FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinatan	D C	20540	
Nashington,	D.C.	20049	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Dowden Nathan J						2. Issuer Name and Ticker or Trading Symbol Entrada Therapeutics, Inc. [TRDA]								all app Direc	licable) tor	ig Perso	Person(s) to Issue 10% Owne Other (spe	
TRADA ΤΗ	,	,		3. Date of Earliest Transaction (Month/Day/Year) 10/20/2022								X	below	below)				
N M	A 0		4. If Amendment, Date of Original Filed (Month/Day/Year)										Form Form	fual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(St	ate) (2	Zip)																
	Table	I - Non	n-Derivat	tive S	Secui	rities	Acc	quir	ed, D	isposed o	f, or l	Benefi	cially	Own	ed			
1. Title of Security (Instr. 3)		Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		TI C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Securities Beneficia Owned Fe		ities icially d Following	Form: I (D) or Indirec	Direct t (I)	7. Nature of Indirect Beneficial Ownership
							С	ode	v	Amount	(A) or (D)	Price		Transa	ransaction(s)		1)	(Instr. 4)
mon Stock 10/20/202			0/20/2022	2				S ⁽¹⁾		905	D	\$18.0	735(2)	6	61,906)	
Stock	ock 10/21/20.		0/21/2022	2				S ⁽¹⁾		2,771	D	\$18.2	85(3)	5	59,135)	
Stock		10/24/202		2			S ⁽¹⁾		1,102	D	\$18.88	18.8809(4)		58,033)		
on Stock 10/24/20		0/24/2022	2				S ⁽¹⁾	П	1,302	D	\$19.63	583 ⁽⁵⁾	56,731		Ι)		
	Tal)wne	d			
2. Conversion or Exercise Price of Derivative Security	onversion Date Execution Date, Captroise (Month/Day/Year) Execution Date, if any (Month/Day/Year) Execution Date, if any if any (Month/Day/Year) Execution Date, if any if an		on Date,	Code (action of Derivativ Securitie Acquirer (A) or Disposer of (D) (Instr. 3, and 5)		ative rities ired osed	Exp (Mo	oiration onth/Day	Date //Year)	3 and 4)		Deri Sec (Ins	vative urity	derivative Securities Beneficially Owned Following Reported	Ov Fo Dir or (I)	vnership rm: rect (D) Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	(Fi FRADA TH STREET N M. (St Security (Ins Stock Stock Stock Stock Stock Stock Stock Stock Stock	(First) (NTRADA THERAPEUTICS, STREET N MA 0 (State) (Z Table Security (Instr. 3) Stock Stock Stock Stock Stock Stock Stock Occurrence of Date (Month/Day/Year)	(First) (Middle) TRADA THERAPEUTICS, INC. STREET N MA 02210 (State) (Zip) Table I - Nor Security (Instr. 3) Stock 1 Stock 1 Table II - Conversion or Exercise Price of Derivative (Month/Day/Year) 3A. Dee Execution if any (Month/Day/Year) (Month/Day/Year)	(First) (Middle) TRADA THERAPEUTICS, INC. STREET Table I - Non-Deriva Security (Instr. 3) Security (Instr. 3) Stock 10/20/2022 Stock 10/24/2022 Table II - Derivative (e.g., pu 2. Transaction Date (Month/Day/Year) Table II - Derivative (e.g., pu	(First) (Middle) TRADA THERAPEUTICS, INC. STREET Table I - Non-Derivative Security (Instr. 3) Stock 10/20/2022 Stock 10/21/2022 Stock 10/24/2022 Table II - Derivative Security e.g., puts, cate of Derivative Security Stock 2. Transaction Date (Month/Day/Year) Stock 10/24/2022 Table II - Derivative Security e.g., puts, cate of Derivative Security 3. Data 10/2 (Month/Day/Year) Stock 10/20/2022 Table II - Derivative Security e.g., puts, cate of Derivative Security 3. Data 10/2 4. Transaction Date if any (Month/Day/Year) Stock 3. Data 10/2 4. Transaction Date if any (Month/Day/Year) Stock 3. Data 10/2	(First) (Middle) TRADA THERAPEUTICS, INC. STREET Table I - Non-Derivative Security (Instr. 3) Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock 10/20/2022 Stock 10/21/2022 Stock 10/24/2022 Table II - Derivative Security (e.g., puts, calls, volume of Exercise Price of Derivative (Month/Day/Year) 2. (Month/Day/Year) 3. Date of E 10/20/2022 4. If Amendication and Execution of Exercise (Month/Day/Year) 3. Date of E 10/20/2022 4. If Amendication and Execution Date (e.g., puts, calls, volume of Exercise Price of Derivative (Month/Day/Year) 3. Date of E 10/20/2022 4. If Amendication and Execution Date (e.g., puts, calls, volume of Exercise Price of Derivative (e.g., puts, calls, volume of Execution Date (Month/Day/Year) 3. Date of E 10/20/2022 4. If Amendication and Execution Date (e.g., puts, calls, volume of Execution Date (e.g., puts, calls, volume of Execution Date (Month/Day/Year) 3. Date of E 10/20/2022	Entrada Theres (First) (Middle) (First) (Middle) FRADA THERAPEUTICS, INC. STREET Table I - Non-Derivative Securities Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock 10/20/2022 Stock 10/21/2022 Stock 10/24/2022 Table II - Derivative Securities A (e.g., puts, calls, warra (e.g., puts, calls, warra (A) or Exercise Price of Derivative Security Security 2. Table II - Derivative Securities A (e.g., puts, calls, warra (e.g., puts, calls, puts, calls, warra (e.g., puts, calls, warra (e.g., puts, calls, warra (e.g., puts, calls, warra (e.g., puts, calls, warr	Conversion or Exercise Price of Derivative Security Security	Conversion or Exercise Price of Derivative Security Stock 10/24/2022 Stock 10/24/20	Entrada Therapeutics, In Entrada Therapeutics, In	Entrada Therapeutics, Inc. TRDA	Stock 10/20/2022 Stock 10/24/2022 Stock	Entrada Therapeutics, Inc. TRDA	(Check (First) (Middle) (State) (Zip) 3. Date of Earliest Transaction (Month/Day/Year) (Month/Day/Year) (State) (Zip) 4. If Amendment, Date of Original Filed (Month/Day/Year) (Entrada Therapeutics, Inc. TRDA	Entrada Therapeutics, Inc. TRDA Check all applicable) Check all applic	Check all applicable Check Company Check Check Company Check Check	Entrada Therapeutics, Inc. TRDA

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.30 to \$19.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.33 to \$19.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Jared Cohen, as Attorneyin-Fact ** Signature of Reporting Person

10/24/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.